ArticleThe oncologist2022

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers.

Yakun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.